Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Conditions: Anatomic Stage II Breast Cancer; Anatomic Stage IIA Breast Cancer; Anatomic Stage IIB Breast Cancer; Anatomic Stage III Breast Cancer; Anatomic Stage IIIA Breast Cancer; Anatomic Stage IIIB Breast Cancer; Anatomic Stage IIIC Breast Cancer; Clinica l Stage II Esophageal Adenocarcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma; Clinical Stage II Gastric Cancer; Clinical Stage II Gastroesophageal Junction Adenocarcinoma; Clinical Stage IIA Esophageal Adenocarcinoma; Clinical Stage IIA Gastric Cancer; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IIB Esophageal Adenocarcinoma; Clinical Stage IIB Gastric Cancer; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma; Clinical Stage III Esophageal Adenocarcinoma; Clinical Stage III Esop hageal Squamous Cell Carcinoma; Clinical Stage III Gastric Cancer; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Distal Esophagus Squamous Cell Carcinoma; Esophageal Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Limited Stage Small Cell Lung Carcinoma; Malignant Solid Neoplasm; Non-Small Cell Lung Carcinoma; Pancreatic Adenocarcinoma; Pathologic Stage II Esophageal Adenocarcinoma; Pathologic Stage II Esophageal Squamous Cell Carcinoma; Pathologic Stage II Gastric Cancer; Pathologic...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Esophagus Cancer | Gastroenterology | HER2 | Skin Cancer | Sodium | Squamous Cell Carcinoma